Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06994676 · ClinicalTrials.gov registry record · Phase 1
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
A Phase 1 study of Chronic Myeloid Leukemia and High Risk Myelodysplastic Syndrome, sponsored by Crossbow Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 11
- Study locations
NCT06994676: Recruiting Phase 1 study of Chronic Myeloid Leukemia and High Risk Myelodysplastic Syndrome, sponsored by Crossbow Therapeutics.
NCT06994676 is a Phase 1 study of Chronic Myeloid Leukemia and High Risk Myelodysplastic Syndrome that is actively recruiting participants, run by Crossbow Therapeutics. The registered enrollment target is 72 participants, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (65% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06994676, a Phase 1 study of Chronic Myeloid Leukemia and High Risk Myelodysplastic Syndrome, is actively recruiting participants, sponsored by Crossbow Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 11
- Study locations
Study Summary
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will continue CBX-250 until progressive disease (PD) or unacceptable toxicity. All subsequent treatment cycles will be 28 days.
Primary Outcome
Frequency and type of DLT
Conditions Studied
Interventions
- DRUG CBX-250
Study Locations (11)
California
- City of Hope - Duarte
- Stanford Medical Center - Palo Alto
Tennessee
- Sarah Cannon Cancer Institute - Nashville
- Vanderbilt University Medical Center - Nashville
Florida
- Moffitt Cancer Center - Tampa
Illinois
- Northwestern Medicine - Chicago
Massachusetts
- Dana Farber Cancer Institute - Boston
Missouri
- Washington University in St. Louis - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT06994676 shows while recruiting
NCT06994676 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 208-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (65% lower).
The record links to 4 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which CBX-250 is the first listed.
NCT06994676 lists 11 locations in 9 states (California, Tennessee, Florida).
Frequently Asked Questions
What is clinical trial NCT06994676 about?
NCT06994676 is a clinical study titled "A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias". Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be admini...
What is the current status of trial NCT06994676?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-07-16. Estimated completion is 2027-06.
What conditions does trial NCT06994676 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML (Acute Myeloid Leukemia).
What interventions are being tested in trial NCT06994676?
The interventions under investigation include: CBX-250 (DRUG).
Who is sponsoring clinical trial NCT06994676?
This trial is sponsored by Crossbow Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06994676 being conducted?
This trial has 11 study locations across California, Florida, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06994676's enrollment target sits among peer trials
72 17th of 35 higher than 18 of 35 other Chronic Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
KRT-232 and TKI Study in Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia
RECRUITING · Phase 1
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
RECRUITING · Phase 1
-
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI